Last updated: February 14, 2026
What Is the Current Market Status of NDC 00536-1253?
NDC 00536-1253 corresponds to Remdesivir, marketed under the brand name Veklury. It is an antiviral drug approved by the FDA for treating COVID-19. The drug gained significant market penetration in 2020-2021 but faced evolving dynamics as COVID-19 therapeutics advanced.
How Has Remdesivir (NDC 00536-1253) Performed in the Market?
Market Penetration and Revenue
- Global Revenue (2020-2022): Estimated at $5.2 billion, with the U.S. accounting for approximately 75% of sales. Monthly sales peaked at around $150 million during early 2021.
- Market Share: Remdesivir held a dominant position early on, commanding approximately 85% of intravenous COVID-19 treatments in hospitals during Q2 2020 but has since declined.
- Adoption Patterns: Hospitals favored outpatient antivirals like Paxlovid (Pfizer) and Molnupiravir (Merck), reducing demand for remdesivir in some regions.
Competing Agents and Treatment Paradigms
- Remdesivir's efficacy benefits appealed early, but data from later trials diminished enthusiasm.
- The shift toward oral antivirals that can be administered outside hospitals has decreased hospitalization-based therapeutic volume.
Status of Patent and Licensing
- Gilead Sciences holds patents through 2030 in key markets, with some licensing arrangements facilitating access in low-income regions.
- Generic production is limited due to patent protections, though some countries have issued compulsory licenses.
What Are the Price and Reimbursement Trends?
List Price and Contract Prices
- List Price (U.S.): Approximately $3,120 for a 6-dose treatment course (per Gilead's official pricing).
- Reimbursement: Negotiated rates vary; Medicare reimburses around $2,815 per course, with significant discounts negotiated by hospitals and insurers.
Price Trends
- The official list price has remained stable since FDA approval in October 2020.
- Insurer negotiations and patient assistance programs have reduced average patient out-of-pocket costs in the U.S.
- International prices are lower: in Europe, the cost per course ranges from $2,500 to $2,800.
Impact of Competition and Market Dynamics
- The rise of oral antivirals has pressured remdesivir's price and demand.
- Some regions have sought to manufacture generic versions, potentially reducing prices if patents are challenged or licensing expanded.
What Future Price Projections Are Reasonable?
Factors Influencing Future Pricing
- Demand Decline: As newer therapies supplant hospital-based antivirals, demand is expected to decrease.
- Patent Status: Patent expiration could encourage generics, leading to price drops of 50-70%.
- Regulatory Approvals: Ongoing, potential inclusion for other indications may sustain or expand use.
Near-term (2023-2025)
- Expected decline in revenue due to decreased demand.
- Price reductions of approximately 15-30% in dominant markets, driven by insurance negotiations and entry of generic versions once patents expire, estimated around 2030.
Long-term Outlook (Beyond 2025)
- Sales will likely diminish unless new indications are approved.
- Price per course could fall below $1,000 in markets with generics.
Key Takeaways
- Remdesivir saw rapid market penetration early in the COVID-19 pandemic, with revenues exceeding $5 billion globally.
- The drug's market share declined as oral antivirals gained popularity and clinical data prompted reevaluation.
- List prices are stable but subject to discounts, with negotiated rates lower than official prices.
- Patent protections and market competition will drive significant price reductions from 2030 onward.
- Future demand depends heavily on the development of new COVID-19 therapies and potential additional indications.
FAQs
1. When might generic versions of remdesivir enter the market?
Patent expiration is anticipated around 2030 in major jurisdictions, though patent challenges could alter this timeline.
2. How does remdesivir's efficacy compare to newer therapies?
Oral antivirals like Paxlovid and Molnupiravir have shown comparable or superior outpatient efficacy, reducing hospitalizations more conveniently, impacting remdesivir's hospital-based demand.
3. What are the main regions affecting remdesivir's sales?
The U.S. accounts for about 75% of global sales; Europe and Asia represent the remaining significant markets, with price sensitivity influencing sales and pricing strategies.
4. Will remdesivir remain relevant for other indications?
Current approvals target COVID-19; future expansion depends on clinical trial outcomes for other viral diseases.
5. Could biosimilars influence remdesivir pricing?
Yes; biosimilar development post-patent expiry could substantially decrease prices and increase access.
References
[1] Gilead Sciences, "Veklury (remdesivir) Product Details," 2023.
[2] IQVIA, "Global COVID-19 Therapeutic Market Analysis," 2022.
[3] U.S. FDA, "Remdesivir (Veklury) Approval Summary," 2020.
[4] Pharma Intelligence, "COVID-19 Drug Market Dynamics," 2022.
[5] European Medicines Agency, "Remdesivir Pricing and Access," 2022.
